CASI vs. NKGN, ATRA, CDTX, SGMO, IKNA, CRIS, TSBX, CRDL, JSPR, and LIFE
Should you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include NKGen Biotech (NKGN), Atara Biotherapeutics (ATRA), Cidara Therapeutics (CDTX), Sangamo Therapeutics (SGMO), Ikena Oncology (IKNA), Curis (CRIS), Turnstone Biologics (TSBX), Cardiol Therapeutics (CRDL), Jasper Therapeutics (JSPR), and aTyr Pharma (LIFE). These companies are all part of the "biological products, except diagnostic" industry.
NKGen Biotech (NYSE:NKGN) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, NKGen Biotech had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for NKGen Biotech and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.50 equaled NKGen Biotech'saverage media sentiment score.
NKGen Biotech has higher earnings, but lower revenue than CASI Pharmaceuticals.
CASI Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 101.34%. Given NKGen Biotech's higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than NKGen Biotech.
NKGen Biotech has a net margin of 0.00% compared to NKGen Biotech's net margin of -95.24%. CASI Pharmaceuticals' return on equity of -2.50% beat NKGen Biotech's return on equity.
28.5% of NKGen Biotech shares are owned by institutional investors. Comparatively, 14.6% of CASI Pharmaceuticals shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
CASI Pharmaceuticals received 199 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Summary
NKGen Biotech beats CASI Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get CASI Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CASI Pharmaceuticals Competitors List
Related Companies and Tools
